Results 121 to 130 of about 18,592 (302)
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié +16 more
wiley +1 more source
Does a citizen science project describe the biogeography of exotic <i>Aureoboletus projectellus</i> in Poland? An ethnomycological survey. [PDF]
Pietras M +3 more
europepmc +1 more source
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker +16 more
wiley +1 more source
Assessing the feasibility and appropriateness of verbal autopsy using contact information of the deceased from burial records in urban Bangladesh. [PDF]
Hossain AT +22 more
europepmc +1 more source
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad +17 more
wiley +1 more source
Lung Lymphatics in Edema, Inflammation, and Thrombosis. [PDF]
Chou C, Reed HO.
europepmc +1 more source
Art Collector of Colonial Korea: Pak Yŏngch’ŏl’s Art Collecting and Museum [PDF]
Kyunghwa Lee
openalex +1 more source
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande +11 more
wiley +1 more source

